TW202233234A - 抗前肌生成抑制蛋白／潛伏性肌生成抑制蛋白抗體用於治療脊髓性肌萎縮之用途 - Google Patents

抗前肌生成抑制蛋白／潛伏性肌生成抑制蛋白抗體用於治療脊髓性肌萎縮之用途 Download PDF

Info

Publication number
TW202233234A
TW202233234A TW110139566A TW110139566A TW202233234A TW 202233234 A TW202233234 A TW 202233234A TW 110139566 A TW110139566 A TW 110139566A TW 110139566 A TW110139566 A TW 110139566A TW 202233234 A TW202233234 A TW 202233234A
Authority
TW
Taiwan
Prior art keywords
sma
patient
therapy
smn
apiigumab
Prior art date
Application number
TW110139566A
Other languages
English (en)
Chinese (zh)
Inventor
榮 張
萊恩 愛羅比諾
喬治 諾米可司
國臣 宋
Original Assignee
美商供石公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商供石公司 filed Critical 美商供石公司
Publication of TW202233234A publication Critical patent/TW202233234A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110139566A 2020-10-26 2021-10-25 抗前肌生成抑制蛋白／潛伏性肌生成抑制蛋白抗體用於治療脊髓性肌萎縮之用途 TW202233234A (zh)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US202063105850P 2020-10-26 2020-10-26
US63/105,850 2020-10-26
US202063106172P 2020-10-27 2020-10-27
US63/106,172 2020-10-27
US202163200955P 2021-04-05 2021-04-05
US63/200,955 2021-04-05
US202163201157P 2021-04-15 2021-04-15
US63/201,157 2021-04-15
US202163202317P 2021-06-06 2021-06-06
US63/202,317 2021-06-06
US202163202372P 2021-06-08 2021-06-08
US63/202,372 2021-06-08
US202163202900P 2021-06-29 2021-06-29
US63/202,900 2021-06-29
US202163260725P 2021-08-30 2021-08-30
US63/260,725 2021-08-30
US202163261398P 2021-09-20 2021-09-20
US63/261,398 2021-09-20

Publications (1)

Publication Number Publication Date
TW202233234A true TW202233234A (zh) 2022-09-01

Family

ID=78622120

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110139566A TW202233234A (zh) 2020-10-26 2021-10-25 抗前肌生成抑制蛋白／潛伏性肌生成抑制蛋白抗體用於治療脊髓性肌萎縮之用途

Country Status (13)

Country Link
US (1) US20240002490A1 (cg-RX-API-DMAC10.html)
EP (2) EP4232151B1 (cg-RX-API-DMAC10.html)
JP (1) JP2023549455A (cg-RX-API-DMAC10.html)
KR (1) KR20230095998A (cg-RX-API-DMAC10.html)
CN (1) CN116390756A (cg-RX-API-DMAC10.html)
AU (1) AU2021369471A1 (cg-RX-API-DMAC10.html)
CA (1) CA3193909A1 (cg-RX-API-DMAC10.html)
ES (1) ES3058087T3 (cg-RX-API-DMAC10.html)
IL (1) IL302132A (cg-RX-API-DMAC10.html)
MX (1) MX2023004763A (cg-RX-API-DMAC10.html)
PL (1) PL4232151T3 (cg-RX-API-DMAC10.html)
TW (1) TW202233234A (cg-RX-API-DMAC10.html)
WO (1) WO2022093724A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
LT4518970T (lt) 2022-05-04 2026-04-27 Scholar Rock, Inc. Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
WO2026076383A1 (en) 2024-10-06 2026-04-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy
EP4763222A1 (en) * 2025-08-25 2026-06-24 Qilu Pharmaceutical Co., Ltd. A composition comprising apitegromab

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych

Also Published As

Publication number Publication date
CA3193909A1 (en) 2022-05-05
CN116390756A (zh) 2023-07-04
WO2022093724A1 (en) 2022-05-05
JP2023549455A (ja) 2023-11-27
EP4232151A1 (en) 2023-08-30
EP4729069A1 (en) 2026-04-22
MX2023004763A (es) 2023-05-09
IL302132A (en) 2023-06-01
PL4232151T3 (pl) 2026-02-23
ES3058087T3 (en) 2026-03-06
US20240002490A1 (en) 2024-01-04
KR20230095998A (ko) 2023-06-29
AU2021369471A1 (en) 2023-06-15
AU2021369471A9 (en) 2024-02-08
EP4232151B1 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
EP4232151B1 (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
AU2020210134B2 (en) Use of myostatin inhibitors and combination therapies
TW202317175A (zh) 用於重量管理及相關代謝病症之療法
US20250326827A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
US20240358704A1 (en) Combined administration
KR20220054608A (ko) ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
TWI807338B (zh) 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
HK40100646A (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
HK40100646B (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
EA051098B1 (ru) Применение антитела к промиостатину/латентному миостатину для лечения спинальной мышечной атрофии
WO2026076383A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
HK40097101A (en) Use of myostatin inhibitors and combination therapies
HK40043422A (en) Use of myostatin inhibitors and combination therapies
HK1260302B (en) Use of myostatin inhibitors and combination therapies